News for Proteostasis Therapeutics Inc (PTI)

Published at

Apr 24, 2024 9:12 AM

by investing.com

mixed

mixed

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair By Investing.com

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

PTI MGNX

Read more →
Published at

Aug 3, 2023 2:40 PM

by marijuanastocks.com

neutral

neutral

Cara Therapeutics, Inc. (CARA) Appoints Helen M. Boudreau to Board of Directors

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors Cara Therapeutics,…

STTK PTI PINC PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE PEP CARA 0HTC.L

Read more →
Published at

Aug 3, 2023 1:00 PM

by globenewswire.com

neutral

neutral

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors

STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

STTK PTI PINC PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE PEP CARA 0HTC.L

Read more →
Published at

Jun 28, 2023 12:30 PM

by globenewswire.com

mixed

mixed

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

JNCE ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE YMTX PTI IUGNF IMU.AX ABOS

Read more →
Published at

Jan 5, 2023 11:09 PM

by marketscreener.com

mixed

mixed

Yumanity Therapeutics : January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA (Nasdaq) - Form 8-K

January 2023 Developing next-generation immunotherapies that address cancer immune resistance KA Disclaimers and other information Cautionary... | January 5, 2023

PTI YMTX FPRX RACA CRIS

Read more →
Published at

Jan 4, 2023 10:30 PM

by globenewswire.com

mixed

mixed

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing...

PTI MGNX YMTX

Read more →
Published at

Jun 29, 2022 10:05 PM

by globenewswire.com

mixed

mixed

Apexigen Announces Board Appointment and New Chair

Meenu Chhabra Karson appointed to Board succeeding Dr. Kenneth Fong as Chair of the Board...

PTI NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA BCACW BCACU BCAC 0K9E.L VLON

Read more →
Published at

May 14, 2022 4:10 PM

by etfdailynews.com

positive

positive

Yumanity Therapeutics (NASDAQ:YMTX) Lowered to “Hold” at Zacks Investment Research

Read Yumanity Therapeutics (NASDAQ:YMTX) Lowered to “Hold” at Zacks Investment Research at ETF Daily News

YMTX PTI BLQA.DE BLK.MX BLK 0QZZ.L

Read more →
Published at

Feb 28, 2022 10:05 PM

by globenewswire.com

positive

positive

Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors

Global biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning...

VLON PTI NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA 0K9E.L

Read more →
Published at

Jan 21, 2022 11:34 AM

by etfdailynews.com

mixed

mixed

Yumanity Therapeutics (NASDAQ:YMTX) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Yumanity Therapeutics (NASDAQ:YMTX) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has $3.00 target price on the stock. According to Zacks, “Yumanity Therapeutics Inc. is a clinical-stage biopharmaceutical company involved in the treatment of neurodegenerative diseases. […]

YMTX PTI

Read more →